Company Summary - Shire PLC (LSE:SHP)
1,135.00p
16.00p
(1.41%)
FTSE 100 Pharmaceuticals & BiotechnologyMarket cap: £6,367.963m
Review a company's summary page in more detail and see the key fundamentals at a glance. Sign-up to Premium now to make your investment decisions.
Sign-up to Premium's Free 7 Day trial See an improved company summary
Summary
Focuses on attention deficit and hyperactivity disorder, human genetic therapies and gastrointestinal diseases
| Financials - 3rd Quarter (30/10/2009) | ||
|---|---|---|
| Turnover | £m | 1,322.16 |
| Pre-tax Profit | £m | 241.5 |
| EPS | p | 32.63 |
| DPS | p | 5.47 |
| Director | Board Role |
|---|---|
| Matthew Emmens | Chairman |
| Angus Russell | Chief Executive |
| Graham Hetherington | Finance Director |
Products Brands & Subsidiaries
Products & Brands
There are no products for this company.
Subsidiaries
Shire International Licensing BV; Shire Pharmaceuticals Ltd; Shire PLC; Shire Pharmaceuticals Ireland Ltd; Shire US Inc...
Broker Sentiment (9 brokers)
Strong SellStrong Buy
| Heading | Date |
|---|---|
| Shire plc PDMR Shareholding | 12/11/2009 |
| Shire plc FDA Grants Priority Revi... | 04/11/2009 |
| Shire plc Director/PDMR Shareho... | 03/11/2009 |